290 related articles for article (PubMed ID: 34375015)
21. AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).
Academy of Managed Care Pharmacy
J Manag Care Pharm; 2009 Aug; 15(6 Suppl A):S3-57, quiz S58-61. PubMed ID: 19678720
[TBL] [Abstract][Full Text] [Related]
22. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
Berkemeier F; Whaley C; Robinson JC
J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
[TBL] [Abstract][Full Text] [Related]
23. Generic drug cost containment in Medicaid: lessons from five state MAC programs.
Abramson RG; Harrington CA; Missmar R; Li SP; Mendelson DN
Health Care Financ Rev; 2004; 25(3):25-34. PubMed ID: 15229994
[TBL] [Abstract][Full Text] [Related]
24. Inflationary Rebates For Generic Drugs Sold Through Medicaid Saved Billions During 2017-20.
Rome BN; Patel AN; Kesselheim AS
Health Aff (Millwood); 2023 Jun; 42(6):770-778. PubMed ID: 37276474
[TBL] [Abstract][Full Text] [Related]
25. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
Mendoza RL
J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
[TBL] [Abstract][Full Text] [Related]
26. Administrative action on drug pricing: Lessons and opportunities for the Center for Medicare and Medicaid Innovation.
Liu ITT; Lalani HS; Kesselheim AS
J Manag Care Spec Pharm; 2024 Mar; 30(3):290-301. PubMed ID: 38140903
[TBL] [Abstract][Full Text] [Related]
27. Remember the MaineRx.
Kemp R
Appl Health Econ Health Policy; 2014 Feb; 12(1):1-5. PubMed ID: 24420789
[TBL] [Abstract][Full Text] [Related]
28. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
[TBL] [Abstract][Full Text] [Related]
29. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
[TBL] [Abstract][Full Text] [Related]
30. Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis.
Shah ED; Chang L; Lembo A; Staller K; Curley MA; Chey WD
Dig Dis Sci; 2021 Dec; 66(12):4140-4148. PubMed ID: 33433804
[TBL] [Abstract][Full Text] [Related]
31. The short-term impact of Ontario's generic pricing reforms.
Law MR; Ystma A; Morgan SG
PLoS One; 2011; 6(7):e23030. PubMed ID: 21829581
[TBL] [Abstract][Full Text] [Related]
32. The Pay-Twice Critique, Government Funding, and Reasonable Pricing Clauses.
Wolitz RE
J Leg Med; 2019; 39(2):177-211. PubMed ID: 31503531
[TBL] [Abstract][Full Text] [Related]
33. One pill, many prices: variation in prescription drug prices in selected government programs.
Gencarelli DM
Issue Brief George Wash Univ Natl Health Policy Forum; 2005 Aug; (807):1-20. PubMed ID: 16167399
[TBL] [Abstract][Full Text] [Related]
34. Generic Drugs in the United States: Policies to Address Pricing and Competition.
Gupta R; Shah ND; Ross JS
Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
[TBL] [Abstract][Full Text] [Related]
35. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
[TBL] [Abstract][Full Text] [Related]
36. A systematic review of reference pricing: implications for US prescription drug spending.
Lee JL; Fischer MA; Shrank WH; Polinski JM; Choudhry NK
Am J Manag Care; 2012 Nov; 18(11):e429-37. PubMed ID: 23198752
[TBL] [Abstract][Full Text] [Related]
37. Medicaid prescription limits: policy trends and comparative impact on utilization.
Lieberman DA; Polinski JM; Choudhry NK; Avorn J; Fischer MA
BMC Health Serv Res; 2016 Jan; 16():15. PubMed ID: 26772962
[TBL] [Abstract][Full Text] [Related]
38. Differences in the cost of antidepressants across state Medicaid programs.
Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
[TBL] [Abstract][Full Text] [Related]
39. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.
Waxman H; Corr B; Martin K; Duong S
Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802
[TBL] [Abstract][Full Text] [Related]
40. Should the United States government regulate prescription prices? A critical review.
Patterson JA; Carroll NV
Res Social Adm Pharm; 2020 May; 16(5):717-723. PubMed ID: 31248779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
